Spruce Biosciences (SPRB) Competitors $0.09 +0.02 (+21.80%) As of 07/11/2025 03:56 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SPRB vs. SNPX, BTAI, NERV, PHIO, BGXX, EQ, ABP, BCLI, SNSE, and ACXPShould you be buying Spruce Biosciences stock or one of its competitors? The main competitors of Spruce Biosciences include Synaptogenix (SNPX), BioXcel Therapeutics (BTAI), Minerva Neurosciences (NERV), Phio Pharmaceuticals (PHIO), Bright Green (BGXX), Equillium (EQ), Abpro (ABP), Brainstorm Cell Therapeutics (BCLI), Sensei Biotherapeutics (SNSE), and Acurx Pharmaceuticals (ACXP). These companies are all part of the "pharmaceutical products" industry. Spruce Biosciences vs. Its Competitors Synaptogenix BioXcel Therapeutics Minerva Neurosciences Phio Pharmaceuticals Bright Green Equillium Abpro Brainstorm Cell Therapeutics Sensei Biotherapeutics Acurx Pharmaceuticals Spruce Biosciences (NASDAQ:SPRB) and Synaptogenix (NASDAQ:SNPX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations. Which has higher valuation & earnings, SPRB or SNPX? Synaptogenix has lower revenue, but higher earnings than Spruce Biosciences. Synaptogenix is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpruce Biosciences$4.91M0.77-$47.92M-$1.32-0.07SynaptogenixN/AN/A-$12.77M-$10.08-0.89 Does the media prefer SPRB or SNPX? In the previous week, Synaptogenix had 1 more articles in the media than Spruce Biosciences. MarketBeat recorded 1 mentions for Synaptogenix and 0 mentions for Spruce Biosciences. Synaptogenix's average media sentiment score of 1.87 beat Spruce Biosciences' score of 0.00 indicating that Synaptogenix is being referred to more favorably in the news media. Company Overall Sentiment Spruce Biosciences Neutral Synaptogenix Very Positive Do analysts rate SPRB or SNPX? Spruce Biosciences presently has a consensus price target of $1.75, suggesting a potential upside of 1,857.49%. Given Spruce Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Spruce Biosciences is more favorable than Synaptogenix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spruce Biosciences 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Synaptogenix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders hold more shares of SPRB or SNPX? 91.7% of Spruce Biosciences shares are held by institutional investors. Comparatively, 10.3% of Synaptogenix shares are held by institutional investors. 6.9% of Spruce Biosciences shares are held by company insiders. Comparatively, 2.7% of Synaptogenix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is SPRB or SNPX more profitable? Synaptogenix has a net margin of 0.00% compared to Spruce Biosciences' net margin of -555.23%. Spruce Biosciences' return on equity of -62.10% beat Synaptogenix's return on equity.Company Net Margins Return on Equity Return on Assets Spruce Biosciences-555.23% -62.10% -47.49% Synaptogenix N/A -115.28%-58.31% Which has more risk & volatility, SPRB or SNPX? Spruce Biosciences has a beta of 2.4, indicating that its share price is 140% more volatile than the S&P 500. Comparatively, Synaptogenix has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. SummarySpruce Biosciences beats Synaptogenix on 10 of the 14 factors compared between the two stocks. Get Spruce Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SPRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRB vs. The Competition Export to ExcelMetricSpruce BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.78M$872.68M$5.62B$9.10BDividend YieldN/A4.84%5.24%4.00%P/E Ratio-0.101.3828.1820.27Price / Sales0.77239.36428.7098.48Price / CashN/A17.6937.4658.16Price / Book0.056.588.045.49Net Income-$47.92M-$23.83M$3.19B$250.45M7 Day PerformanceN/A1.59%3.62%4.79%1 Month PerformanceN/A12.08%4.06%7.68%1 Year PerformanceN/A4.39%30.00%16.43% Spruce Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPRBSpruce Biosciences2.0688 of 5 stars$0.09+21.8%$1.75+1,857.5%-84.2%$3.78M$4.91M-0.1020High Trading VolumeSNPXSynaptogenix0.3342 of 5 stars$8.50+5.2%$14.00+64.7%+63.3%$11.82MN/A-0.844Positive NewsGap DownBTAIBioXcel Therapeutics4.26 of 5 stars$1.90-1.6%$42.60+2,142.1%-89.7%$11.69M$2.27M-0.1490News CoverageNERVMinerva Neurosciences4.2441 of 5 stars$1.64-0.6%$5.00+204.9%-48.4%$11.54MN/A2.009News CoveragePHIOPhio Pharmaceuticals2.5721 of 5 stars$2.55+6.3%$14.00+449.0%-60.5%$11.52MN/A-0.4010BGXXBright GreenN/AN/AN/AN/A$11.47MN/A-1.002Gap DownEQEquillium2.9236 of 5 stars$0.32-0.6%$3.00+840.4%-54.0%$11.47M$41.10M-0.8240News CoverageGap DownABPAbproN/A$0.19-0.6%$4.00+2,040.2%N/A$11.43M$180K0.0015Positive NewsBCLIBrainstorm Cell Therapeutics1.4474 of 5 stars$1.14-1.7%$30.00+2,531.6%-80.0%$11.41MN/A-0.3440SNSESensei Biotherapeutics4.6718 of 5 stars$9.15+1.3%$90.00+883.6%-40.1%$11.39MN/A-0.4040Positive NewsGap DownACXPAcurx Pharmaceuticals2.5826 of 5 stars$0.47-2.2%$8.00+1,597.1%-79.4%$11.32MN/A-0.673 Related Companies and Tools Related Companies Synaptogenix Competitors BioXcel Therapeutics Competitors Minerva Neurosciences Competitors Phio Pharmaceuticals Competitors Bright Green Competitors Equillium Competitors Abpro Competitors Brainstorm Cell Therapeutics Competitors Sensei Biotherapeutics Competitors Acurx Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRB) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredDid you miss out on Trump’s “birthday gift” to Americans?While protestors were rallying against “King Trump,” one trader quietly spotted a 15% weekend move tied to his...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spruce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spruce Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SPRB Stock Alerts